Six presented abstracts at ASCO-GU 2026 reinforce the clinical impact of Myriad’s Precise MRD, Prolaris, and MyRisk tests

These abstracts and posters will be presented at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, which will be held Feb. 26-28 at the Moscone West Conference Center, ...
CURE

MRD Testing May Offer Peace of Mind to Breast Cancer Survivors

Minimal residual disease, or MRD, testing may have the potential to offer peace of mind to survivors of breast cancer, as a ...
STAT

Can MRD testing reshape adjuvant and surveillance decisions in cancer care?

Clinicians have long relied on clinical risk factors, imaging, and pathology to guide cancer surveillance and adjuvant treatment. However, even after curative-intent surgery and definitive therapy, ...
Business Wire

Personalis Pioneers Advancement in MRD Testing with the Launch of its Real-Time Variant Tracker™

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the early access launch of Real-Time Variant Tracker, a powerful new option ...
Nasdaq

Myriad Genetics Unveils Promising Clinical Data on Precise MRD Test for Oligometastatic Clear-Cell Renal Cell Carcinoma at AACR Annual Meeting

Myriad Genetics will present new data on its Precise MRD test for renal cell carcinoma at the AACR Annual Meeting. Myriad Genetics, Inc. announced that it will present new clinical data on its Precise ...
Morningstar

Labcorp Expands MRD Testing for Breast, Lung and Colon Cancer Recurrence Risk

Molecular residual disease (MRD) testing detects cancer recurrence months before traditional imaging Labcorp MRD tests now monitor recurrence risk across stage I–III breast cancer, stage I–IIIA ...
Morningstar

Phase III PALLAS Study Shows Signatera™ MRD Testing Provides Powerful Post‑Surgical Prognostic Information in Patients with High and Intermediate Risk HR+/HER2‑ Breast Cancer

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, together with Alliance Foundation Trials, LLC (AFT) and the Austrian Breast and Colorectal Cancer Study Group ...
The American Journal of Managed Care

Using MRD, Patient Preference to Optimize Multiple Myeloma Care

Hans Lee, MD, explores how minimal residual disease (MRD) testing guides treatment decisions for multiple myeloma and highlights the value of patient preferences. Minimal residual disease (MRD) ...
Seeking Alpha

Blood-based MRD Test for Cancer Recurrence Can Generate Cost Savings in Colorectal Cancer Treatment, Finds Study in JAMA Health Forum

Circulating tumor DNA (ctDNA) testing for minimal residual disease (MRD) can reduce costs by up to 21% across health plan populations when half of eligible patients with stage II colorectal cancer are ...

Adaptive Biotechnologies targets $1,300 ASP for MRD tests in 2025 driven by pricing improvements

CEO Chad Robins highlighted a strong year for Adaptive Biotechnologies, with MRD revenue increasing by 42% year-over-year.
ascopubs.org

Prospective Validation of Circulating Tumor DNA Measurable Residual Disease After First-Line Therapy in Large B-Cell Lymphoma

Automated Lymph Node and Extranodal Extension Assessment Improves Risk Stratification in Oropharyngeal Carcinoma Patients were enrolled in the HOVON-902 prospective cohort and received curative-intent ...